Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07787156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07787156 · ClinicalTrials.gov record · last posted 2026-08-26

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

Study acronym: REGENERATE
StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study participation.
Trial Details
NCT Number NCT07787156
Lead Sponsor Brigham and Women's Hospital
Collaborators: Pancreatic Cancer Action Network, Exact Science Corporation, Dana-Farber Cancer Institute, Winn Career Development Award
Conditions Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Enrollment 80 participants
Start Date 2026-09
Primary Completion 2028-09 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-26